Nocturia
A prospective study of 112 people showed silodosin reduced the number of nocturia episodes by a mean of 1.1 episodes per night. (1)
A recent study of 7343 men, half of whome took dutasteride showed nocturia was associated with increased mortality risk (hazard ratio [HR] = 1.72; 95% CI 1.15–2.55) independent from demographics and medical comorbidities. (2) Another study showed death HR of 1.4 with daytime frequency or nocturia. (3)
A 2020 study found a HR of mortality of 1.46 for 1 time, 1.85 to 2 times or 2.06 for 3 or more times of nocturia. (4)
A recent study of 7343 men, half of whome took dutasteride showed nocturia was associated with increased mortality risk (hazard ratio [HR] = 1.72; 95% CI 1.15–2.55) independent from demographics and medical comorbidities. (2) Another study showed death HR of 1.4 with daytime frequency or nocturia. (3)
A 2020 study found a HR of mortality of 1.46 for 1 time, 1.85 to 2 times or 2.06 for 3 or more times of nocturia. (4)
- Cho, Kang Jun, et al. "Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: A multi-center, prospective, open-label, single-arm, phase IV trial." Urology (2018).
- Bliwise, Donald L., et al. "Nocturia and associated mortality: observational data from the REDUCE trial." Prostate cancer and prostatic diseases (2018): 1.
- Åkerla, Jonne, et al. "Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men." Prostate Cancer and Prostatic Diseases(2018): 1.
- Funada, Satoshi, et al. "Impact of Nocturia on Mortality: The Nagahama Study." The Journal of Urology (2020): 10-1097.